May 21^st marked a new beginning in the future of Odin Pharmaceuticals/Somerset Therapeutics/Pharma with the groundbreaking ceremony held at its facility in Somerset, NJ to expand its facility to 110,000 square foot building. The construction is expected to take 12 months and the new facility will house multiple manufacturing lines and an expanded R&D center. This is in line with the group’s strategy to continue to onshore a significant portion of its sterile manufacturing to enable greater flexibility and risk mitigation to meet the needs of US hospitalized and outpatients and contribute to saving lives.

This expansion will create further opportunities for employment and supplemental business growth in and around the community and state. While our strategy to set up manufacturing facilities in the US has been part of our ongoing process, it aligns with the current thinking of the US government and the larger needs of US healthcare for onshore manufacturing of critical drug products.

Ilango Subramanian– The President and COO of the group stated “With this expansion, the company is on its way to becoming a diversified pharmaceutical player with products across multiple delivery systems to meet the demand for affordable medicine in the US across different therapeutic areas.